Phenominer Database Results (156 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 62.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67855 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67856 829
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67860 829
DA.ACI-(D10Rat2-D10Rat6) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68207 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68204 829
DA.ACI-(D10Rat10-D10Rat142) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 6 13.5 d 3.1 7.59 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68218 829
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 7 71.4 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68219 829
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 12 1.0 % 0.78 2.7 body weighing method 0.0 intradermal injection 40 days from before p.i. 68712 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 12 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68710 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68717 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 3 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68721 839
DA.ACI-(D10Rat2-D10Rat29)/Kini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 8 0.0 % 0.0 0.0 body weighing method 0.0 intradermal injection 40 days from before p.i. 68725 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 37.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68732 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 7 0.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68733 829
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 7 14.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68734 829
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 24 33.0 d in vivo visual assessment 0.0 subcutaneous injection from 8 to38 days 69382 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 50.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69384 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 33.9 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 40 days 69388 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 18 94.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days 69390 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 18 20.9 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38 days days 69393 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 22.6 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days days 69396 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 7 16.3 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 40 days 69413 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 14.1 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 40 days 69410 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 7 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69412 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 14 18.4 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69417 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 14 28.9 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 34 days 69433 892
DA.ACI-(D10Rat219-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 7.4 d 1.2 4.33 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68230 829
DA.ACI-(D10Rat2-D10Rat29)/Kini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 7 0.0 % 0.0 0.0 body weighing method 0.0 intradermal injection 40 days from before p.i. 68728 839
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65.0 days-112.0 days 21 11.7 d 2.23 10.2 in vivo visual assessment 0.0 69490 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91.0 days-112.0 days 21 76.0 % in vivo visual assessment 0.0 visual observation 69488 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65.0 days-112.0 days 22 15.8 d 1.9 8.9 in vivo visual assessment 0.0 69489 837
DA.PVG.1AV1-(D4Got126-D4Got136) ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63.0 days-150.0 days 19 0.0 % necropsy 0.0 intradermal injection visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68127 838
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 21 100.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 DA.PVG.1AV1-(D4Got128-D4Got136) for strain 68130 838
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 12 19.7 d 2.48 8.6 in vivo visual assessment 0.0 69376 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 80.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67849 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 100.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67850 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 12 3.5 d 1.7 5.89 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68194 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68201 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 14 13.4 d 2.2 8.23 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68209 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 30.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68213 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 8 87.5 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68709 839
DA.ACI-(D10Rat2-D10Rat29)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 3 14.7 d 1.44 2.5 in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68719 839
DA.ACI-(D10Rat2-D10Rat29)/Kini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 10 0.0 % 0.0 0.0 body weighing method 0.0 intradermal injection 40 days from before p.i. 68723 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 30.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68718 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68722 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 7 14.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68726 839
DA.ACI-(D10Rat2-D10Rat29)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 1 23.0 d in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68727 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 33.8 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 40 days 69385 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 28 10.7 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days days 69381 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 6.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days days 69386 892
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 100.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69409 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 14 11.2 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 40 days 69416 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 19 17.3 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 28 days 69420 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 32.8 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 34 days 69427 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 30.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69426 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 9 5.9 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69432 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 14 7.8 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69434 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 14 18.5 d 1.6 5.99 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68224 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 30.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68228 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 25.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days expressed as a fraction of total number of animals 68231 829
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 13 69.0 % in vivo visual assessment 0.0 68123 837
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 1 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68729 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65.0 days-112.0 days 22 19.6 d 2.22 10.4 in vivo visual assessment 0.0 69493 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 65.0 days-112.0 days 21 21.9 d 2.47 11.3 in vivo visual assessment 0.0 69494 837
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 89.0 % 33.0 in vivo visual assessment 0.0 visual observation 69497 837
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 81.2 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67874 829
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 53.8 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67876 829
DA/ZtmKini ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63.0 days-150.0 days 20 0.0 % necropsy 0.0 intradermal injection visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68125 838
N:HS percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (50-120 ug) and Freund's complete adjuvant (100 ul) Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 central nervous system integrity trait both 132.0 days-177.0 days 217 41.0 % in vivo visual assessment 0.0 66040 114
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67852 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 12 8.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68195 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 70.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68198 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 16.4 d 2.6 7.35 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68200 829
DA.ACI-(D10Rat2-D10Rat6) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 18.9 d 2.2 6.22 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68206 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 4 8.7 d 2.8 5.6 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68212 829
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 40.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68216 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68714 839
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 10 2.8 % 1.26 4.0 body weighing method 0.0 intradermal injection 40 days from before p.i. 68716 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 8 0.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68724 839
DA.ACI-(D10Rat2-D10Rat29)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 75.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68735 829
ACI/SegHsd percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70.0 days-145.0 days 21 5.0 % in vivo visual assessment 0.0 69970 1279
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 24 5.5 d in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days days 69383 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 18.2 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 31days 69395 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 11 17.4 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 38days 69407 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 11 91.0 % in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69406 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 23.8 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69411 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 21 11.5 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69419 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 21 16.2 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 28 days 69422 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 17 9.0 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69425 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 18 6.0 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69430 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 6 7.5 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69437 892
DA.ACI-(D10Rat12-D10Rat144) percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 38.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days relap, % 68222 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait male 91.0 days-112.0 days 22 82.0 % in vivo visual assessment 0.0 visual observation 69487 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 10.1 d 9.5 in vivo visual assessment 0.0 69502 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 69.0 % 48.0 in vivo visual assessment 0.0 visual observation 69498 837
DA.PVG.1AV1-(D4Got126-D4Got136) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 19 10.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 DA.PVG.1AV1-(D4Got128-D4Got136) for strain 68126 838
DA/ZtmKini ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63.0 days-150.0 days 23 61.0 % necropsy 0.0 intradermal injection visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68129 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 23 100.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68128 838
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 87.5 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67853 829
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 56.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68210 829
DA.ACI-(D10Rat219-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 6 11.5 d 2.6 6.37 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68215 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 11 100.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68132 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 8 16.2 d 0.92 2.6 in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68707 839
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 10 3.5 % 1.49 4.7 body weighing method 0.0 intradermal injection 40 days from before p.i. 68708 839
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 10 80.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 68706 839
DA.ACI-(D10Rat2-D10Rat29)/Kini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 10 1.2 % 1.14 3.6 body weighing method 0.0 intradermal injection 40 days from before p.i. 68720 839
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 1 3.0 d 0.0 0.0 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68730 829
DA.ACI-(D10Rat2-D10Rat29)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 6 13.3 d 2.6 6.37 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68731 829
DA/Ztm percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90. central nervous system integrity trait not specified 70.0 days-145.0 days 36 72.0 % in vivo visual assessment 0.0 69969 1279
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 28 64.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to 37 days 69378 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 28 26.5 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 37 days 69380 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 24 33.0 % in vivo visual assessment 0.0 subcutaneous injection 37 days from 8 to38 days 69379 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 19 100.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69397 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 19 11.8 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days days 69399 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 11 17.6 d in vivo visual assessment 0.0 subcutaneous injection 38 days from 8 to 38days 69408 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 7 22.4 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69414 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 14 86.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69415 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 17 25.2 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 34 days 69424 892
DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 21 13.3 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69423 892
DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 18 31.2 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 34 days 69429 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 2.7 d in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69428 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 6 28.3 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 34 days 69436 892
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 16 81.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68225 829
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 13 22.5 d 3.58 12.9 in vivo visual assessment 0.0 69492 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 12 14.8 d 2.4 8.3 in vivo visual assessment 0.0 69491 837
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 15.6 d 9.4 in vivo visual assessment 0.0 69499 837
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 22.5 d 12.9 in vivo visual assessment 0.0 69500 837
DA.ACI-(D10Rat10-D10Rat142) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 7 85.7 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67875 829
DA.PVG.1AV1-(D4Got126-D4Got136) ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. total life span both 63.0 days-150.0 days 21 24.0 % necropsy 0.0 intradermal injection visual observation ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time (CMO:0003802) 68131 838
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 12 33.3 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67848 829
DA.ACI-(D10Rat15-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 13 76.9 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67859 829
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 8 13.0 d 1.8 5.09 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68197 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 5 13.4 d 2.0 4.47 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68203 829
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 11 14.9 d 1.03 3.4 in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68133 839
DA/ZtmKini maximum body weight loss to initial body weight ratio myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. body mass male 103.0 days-131.0 days 11 14.4 % 2.47 8.2 body weighing method 0.0 intradermal injection 40 days from before p.i. CMO:0001400 68134 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 11 91.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68135 839
DA/ZtmKini percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 6 50.0 % in vivo visual assessment 0.0 intradermal injection 40 days from p.i. day 7 CMO:0001402 68713 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 6 21.2 d 0.53 1.3 in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68711 839
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (20 ug) Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5. central nervous system integrity trait male 103.0 days-131.0 days 8 19.2 d 1.24 3.5 in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68715 839
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 38.0 % in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days 69387 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 16 4.9 d in vivo visual assessment 0.0 subcutaneous injection 40 days from 8 to 40 days days 69389 892
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 18 14.3 d in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31 days days 69392 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 18 16.7 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 38 days 69391 892
DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 10 90.0 % in vivo visual assessment 0.0 subcutaneous injection 31 days from 8 to 31days 69394 892
DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 19 15.8 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 31days days 69398 892
DA/ZtmKini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 21 18.7 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 28 days 69418 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 19 11.2 d in vivo visual assessment 0.0 subcutaneous injection 28 days from 8 to 28 days 69421 892
DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini post-insult time to onset of experimental autoimmune encephalomyelitis myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 9 28.4 d in vivo visual assessment 0.0 subcutaneous injection from 8 to 34 days 69431 892
DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days) Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13. central nervous system integrity trait female  days 6 50.0 % in vivo visual assessment 0.0 subcutaneous injection 34 days from 8 to 34 days 69435 892
DA.ACI-(D10Rat12-D10Rat144) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 7 14.4 d 2.8 7.41 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68221 829
DA.ACI-(D10Rat15-D10Rat29) experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 8.6 d 1.5 4.74 in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 68227 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 91.0 days-112.0 days 12 92.0 % in vivo visual assessment 0.0 68122 837
DA/ZtmKini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 20.0 d 8.5 in vivo visual assessment 0.0 69501 837
DA.ACI-(D10Rat219-D10Rat29) percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (200 ul) Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73. central nervous system integrity trait not specified 63.0 days-105.0 days 10 60.0 % in vivo visual assessment whole animal 0.0 injection 40 days range 31 to 40 days 67873 829
DA/ZtmKini percentage of study population developing experimental autoimmune encephalomyelitis during a period of time myelin oligodendrocyte glycoprotein (20 ug/200 ul) Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24. central nervous system integrity trait both 63.0 days-150.0 days 20 60.0 % in vivo visual assessment 0.0 intradermal injection from p.i. day 7 68124 838
DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini experimental autoimmune encephalomyelitis duration myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716. central nervous system integrity trait female 65.0 days-112.0 days 13 10.1 d 2.63 9.5 in vivo visual assessment 0.0 69377 837